MCID: BCT006
MIFTS: 30

Bacterial Conjunctivitis malady

Categories: Eye diseases, Infectious diseases, Cardiovascular diseases, Respiratory diseases, Gastrointestinal diseases, Nephrological diseases

Aliases & Classifications for Bacterial Conjunctivitis

Aliases & Descriptions for Bacterial Conjunctivitis:

Name: Bacterial Conjunctivitis 12 14 69
Conjunctivitis, Bacterial 42
Purulent Conjunctivitis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:9700
ICD10 33 H10.0
MeSH 42 D003234
NCIt 47 C53656
UMLS 69 C0009768

Summaries for Bacterial Conjunctivitis

MalaCards based summary : Bacterial Conjunctivitis, also known as conjunctivitis, bacterial, is related to conjunctivitis and typhoid fever. An important gene associated with Bacterial Conjunctivitis is GCNT2 (Glucosaminyl (N-Acetyl) Transferase 2, I-Branching Enzyme (I Blood Group)). The drugs Dexamethasone and Tobramycin have been mentioned in the context of this disorder. Affiliated tissues include eye and testes.

Related Diseases for Bacterial Conjunctivitis

Diseases in the Conjunctivitis family:

Acute Conjunctivitis Chronic Conjunctivitis
Bacterial Conjunctivitis

Diseases related to Bacterial Conjunctivitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 11)
id Related Disease Score Top Affiliating Genes
1 conjunctivitis 10.7
2 typhoid fever 9.9 CD79A TTC37
3 keratitis 9.9
4 purulent endophthalmitis 9.9 CD79A GCNT2
5 ophthalmomyiasis 9.6
6 trachoma 9.6
7 blepharoconjunctivitis 9.6
8 pneumonia 9.6
9 influenza 9.6
10 haemophilus influenzae 9.6
11 renal tuberculosis 9.2 CD79A GCNT2 KRT15 PURA TTC37

Graphical network of the top 20 diseases related to Bacterial Conjunctivitis:



Diseases related to Bacterial Conjunctivitis

Symptoms & Phenotypes for Bacterial Conjunctivitis

Drugs & Therapeutics for Bacterial Conjunctivitis

Drugs for Bacterial Conjunctivitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 134)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 50-02-2 5743
2
Tobramycin Approved, Investigational Phase 4,Phase 3 32986-56-4 5496 36294
3
Dipivefrin Approved Phase 4,Phase 3,Phase 2 52365-63-6 3105
4
Cyclosporine Approved, Investigational, Vet_approved Phase 4 79217-60-0, 59865-13-3 5284373 6435893
5
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 50-28-2 5757 53477783
6
Ivermectin Approved, Vet_approved Phase 4 70288-86-7 6474909 46936176
7
Ephedrine Approved Phase 4,Phase 2,Phase 3 299-42-3 9294
8
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
9
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2 22916-47-8 4189
10
Azithromycin Approved Phase 4,Phase 3,Phase 2 83905-01-5 55185 53477736 447043
11
Norgestimate Approved Phase 4,Phase 3,Phase 2 35189-28-7 6540478
12
Ofloxacin Approved Phase 4,Phase 2,Phase 3 82419-36-1 4583
13
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2 564-25-0 54671203
14
Permethrin Approved, Investigational Phase 4 52645-53-1 40326
15
Moxifloxacin Approved, Investigational Phase 4,Phase 3,Phase 2 354812-41-2, 151096-09-2 152946
16
Trimethoprim Approved, Vet_approved Phase 4,Phase 3 738-70-5 5578
17
Pseudoephedrine Approved Phase 4,Phase 2,Phase 3 90-82-4 7028
18
Albendazole Approved, Vet_approved Phase 4 54965-21-8 2082
19
Loteprednol Approved Phase 4,Phase 3 82034-46-6, 129260-79-3 444025 9865442
20
Gatifloxacin Approved, Investigational Phase 4,Phase 3,Phase 2 112811-59-3 5379
21
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
22
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 2 57-63-6 5991
23
Levofloxacin Approved, Investigational Phase 4,Phase 2,Phase 3 100986-85-4 149096
24
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
25
Menthol Approved Phase 4 2216-51-5 16666
26 Polymyxin B Phase 4,Phase 3
27 Dexamethasone acetate Phase 4,Phase 3,Phase 2 1177-87-3
28 glucocorticoids Phase 4,Phase 3,Phase 2
29
protease inhibitors Phase 4,Phase 3,Phase 2
30 Gastrointestinal Agents Phase 4,Phase 3,Phase 2
31 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2
32 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
33 Hormone Antagonists Phase 4,Phase 3,Phase 2
34 Dexamethasone 21-phosphate Phase 4,Phase 3,Phase 2
35 Hormones Phase 4,Phase 3,Phase 2
36 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
37 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
38 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
39 Polymyxins Phase 4,Phase 3
40 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
41 Anti-Infective Agents, Local Phase 4,Phase 3
42 Antiemetics Phase 4,Phase 3,Phase 2
43 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2
44 BB 1101 Phase 4,Phase 3,Phase 2
45 Autonomic Agents Phase 4,Phase 3,Phase 2
46 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2
47 Estradiol valerate Phase 4,Phase 3,Phase 2 979-32-8
48 Prednisolone acetate Phase 4
49 Nasal Decongestants Phase 4,Phase 2,Phase 3
50 Neuroprotective Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 84)
id Name Status NCT ID Phase
1 Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora Completed NCT00312338 Phase 4
2 Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment Completed NCT00798577 Phase 4
3 A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis Completed NCT00464438 Phase 4
4 Partnership for Rapid Elimination of Trachoma Completed NCT00792922 Phase 4
5 Impact of Water and Health Education Programs on Trachoma and Ocular C. Trachomatis in Niger Completed NCT00348478 Phase 4
6 Effect of Intensive Fly Control on Trachoma and Ocular Chlamydia Infection in Tanzania Completed NCT00347763 Phase 4
7 Study of Three Alternatives for Mass Treatment in Trachoma Villages of Tanzania Completed NCT00347607 Phase 4
8 A Trial of Non-absorbable Versus Absorbable Sutures for Trichiasis Surgery Completed NCT00522860 Phase 4
9 Tripartite International Research for the Elimination of Trachoma Completed NCT01202331 Phase 4
10 Trachoma Amelioration in Northern Amhara (TANA) Completed NCT00322972 Phase 4
11 Impact of Two Alternative Dosing Strategies for Trachoma Control in Niger Completed NCT00618449 Phase 4
12 Trachoma Elimination Follow-up Completed NCT00221364 Phase 4
13 Moxifloxacin vs. Polytrim for Conjunctivitis Completed NCT00581542 Phase 4
14 Topical Cyclosporine for Vernal Keratoconjunctivitis (VKC) in Rwanda Completed NCT01211327 Phase 4
15 Safety and Efficacy of Zylet vs Lotemax, Tobramycin and Vehicle in Pediatric Blepharoconjunctivitis Completed NCT00705159 Phase 4
16 A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Dry Eye Disease Completed NCT01014078 Phase 4
17 A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Rewetting Drops in Subjects With History and Current Complaint of Contact Lens-Related Dry Eye (CLDE) Completed NCT01105624 Phase 4
18 Zylet vs TobraDex in Blepharokeratoconjunctivitis Completed NCT00447577 Phase 4
19 A Study of Sodium Carboxymethylcellulose for Post Cataract Surgery Dry Eye Symptoms Completed NCT02028754 Phase 4
20 Sanitation, Water, and Instruction in Face-washing for Trachoma Recruiting NCT02754583 Phase 4
21 A Surveillance and Azithromycin Treatment for Newcomers and Travelers Evaluation: The ASANTE Trial Active, not recruiting NCT01767506 Phase 4
22 Water Uptake for Health in Amhara Pilot Active, not recruiting NCT02373657 Phase 4
23 Effect of Benzalkonium Chloride Containing Eye Drops on the Conjunctival Bacterial Flora of Dry Eye Patients Not yet recruiting NCT02533154 Phase 4
24 Effect of Topical Azithromycin on Tear Film Thickness in Patients With Meibomian Gland Dysfunction Not yet recruiting NCT03162497 Phase 4
25 Azithromycin in Control of Trachoma II Withdrawn NCT00286026 Phase 4
26 Safety Study of Combined Azithromycin, Ivermectin and Albendazole for Trachoma and Lymphatic Filariasis Withdrawn NCT01903057 Phase 4
27 Effectiveness Comparison Between the Drugs TOBRACORT® and TOBRADEX® in Reducing the Signs and Symptoms of Acute Bacterial Conjunctivitis Unknown status NCT01227915 Phase 3
28 Efficacy Maxinom® And Maxitrol® in Reducing The Signs And Symptoms Of Acute Bacterial Conjunctivitis Unknown status NCT01227863 Phase 3
29 Evaluate the Use of Ganciclovir Gel 0.3% for the Treatment of Conjunctivitis Caused by Adenovirus Unknown status NCT01600365 Phase 3
30 A Study to Determine if 0.6% ISV-403 is Safe and Effective in the Treatment of Bacterial Conjunctivitis. Completed NCT00347932 Phase 3
31 Study of Efficacy of Levofloxacin 0.5% Ophthalmic Solution Administered Three Times a Day for Bacterial Conjunctivitis Completed NCT00565123 Phase 2, Phase 3
32 AL-15469A for the Treatment of Bacterial Conjunctivitis Completed NCT00331916 Phase 3
33 AL-15469A for the Treatment of Bacterial Conjunctivitis Completed NCT00332293 Phase 3
34 Efficacy and Safety of T1225 1.5% Versus Tobramycin 0.3 % in the Treatment of Purulent Bacterial Conjunctivitis Completed NCT00357773 Phase 3
35 An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% ((VIGAMOX®) Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese Patients Completed NCT01573910 Phase 3
36 Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Tobramycin for Bacterial Conjunctivitis (C-01-401-004) Completed NCT00105469 Phase 3
37 Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Vehicle for Bacterial Conjunctivitis (C-01-401-003) Completed NCT00105534 Phase 3
38 A Study to Investigate the Safety and Efficacy of BOL-303224 in the Treatment of Bacterial Conjunctivitis Completed NCT00348348 Phase 3
39 Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis Completed NCT00972777 Phase 2, Phase 3
40 Moxifloxacin AF Ophthalmic Solution for Treatment of Bacterial Conjunctivitis Completed NCT00759148 Phase 3
41 A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis Completed NCT00518089 Phase 3
42 A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis Completed NCT00509873 Phase 3
43 Clinical Efficacy and Safety of T1225 Versus Tobramycin 0.3 % Eye Drops in the Treatment of Purulent Bacterial Conjunctivitis of Children. Completed NCT01155999 Phase 3
44 Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehicle Completed NCT01175590 Phase 3
45 Safety/Efficacy of Antibiotic Steroid Combination in Treatment of Blepharitis and/or Keratitis and/or Conjunctivitis Completed NCT00732446 Phase 3
46 Efficacy and Safety of 2 Dosing Regimens of T1225 Eye Drops 1.5% Versus Oral Azithromycin in Treatment of Trachoma Completed NCT00356720 Phase 3
47 Clinical Trial of Eye Prophylaxis in the Newborn Completed NCT00000120 Phase 3
48 Comparative Study of AzaSite Plus Compared to AzaSite Alone and Dexamethasone Alone to Treat Subjects With Blepharoconjunctivitis Completed NCT00578955 Phase 3
49 Loteprednol and Tobramycin Versus Tobramycin and Dexamethasone, in the Treatment of Blepharokeratoconjunctivitis Completed NCT01028027 Phase 3
50 Prophylactic Antibiotics in Measles Completed NCT00168532 Phase 3

Search NIH Clinical Center for Bacterial Conjunctivitis

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: conjunctivitis, bacterial

Genetic Tests for Bacterial Conjunctivitis

Anatomical Context for Bacterial Conjunctivitis

MalaCards organs/tissues related to Bacterial Conjunctivitis:

39
Eye, Testes

Publications for Bacterial Conjunctivitis

Articles related to Bacterial Conjunctivitis:

(show top 50) (show all 146)
id Title Authors Year
1
Besifloxacin Ophthalmic Suspension 0.6% Compared with Gatifloxacin Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis in Neonates. ( 28078599 )
2017
2
Neonatal Bacterial Conjunctivitis in Korea in the 21st Century. ( 28002109 )
2016
3
A 3-day regimen with azithromycin 1.5% eyedrops for the treatment of purulent bacterial conjunctivitis in children: efficacy on clinical signs and impact on the burden of illness. ( 25945033 )
2015
4
Preparation and in vitro/in vivo evaluation of antimicrobial ocular in situ gels containing a disappearing preservative for topical treatment of bacterial conjunctivitis. ( 25886078 )
2015
5
Deep subconjunctival injection of gentamicin for the treatment of bacterial conjunctivitis in macaques (Macaca mulatta and Macaca fascicularis). ( 25693106 )
2015
6
Efficacy and safety of azithromycin 1.5% eye drops in paediatric population with purulent bacterial conjunctivitis. ( 24526744 )
2014
7
Gatifloxacin 0.5% Administered Twice Daily for the Treatment of Acute Bacterial Conjunctivitis in Patients One Year of Age or Older. ( 25244402 )
2014
8
The role of besifloxacin in the treatment of bacterial conjunctivitis. ( 24566460 )
2014
9
An evaluation of the reclassification of ophthalmic chloramphenicol for the management of acute bacterial conjunctivitis in community pharmacies in Western Australia. ( 24841453 )
2014
10
Epidemiological study of hospital-acquired bacterial conjunctivitis in a level III neonatal unit. ( 23766676 )
2013
11
A case of recalcitrant bacterial conjunctivitis. ( 24555257 )
2013
12
External ophthalmomyiasis caused by Oestrus ovis misdiagnosed as bacterial conjunctivitis. ( 23780871 )
2013
13
Identification of causative pathogens in eyes with bacterial conjunctivitis by bacterial cell count and microbiota analysis. ( 23246122 )
2013
14
A new diagnostic index for bacterial conjunctivitis in primary care. A re-derivation study. ( 24256320 )
2013
15
The safety of besifloxacin ophthalmic suspension 0.6 % used three times daily for 7 days in the treatment of bacterial conjunctivitis. ( 24142473 )
2013
16
Bacterial conjunctivitis: a review of therapies and approaches. ( 23189448 )
2012
17
Bacterial conjunctivitis. ( 22348418 )
2012
18
Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infections. ( 23233796 )
2012
19
Besifloxacin ophthalmic suspension, 0.6%: a novel topical fluoroquinolone for bacterial conjunctivitis. ( 22729919 )
2012
20
Microbiological etiology and susceptibility of bacterial conjunctivitis isolates from clinical trials with ophthalmic, twice-daily besifloxacin. ( 22644963 )
2012
21
Gatifloxacin ophthalmic solution for treatment of bacterial conjunctivitis: safety, efficacy and patient perspective. ( 23650458 )
2012
22
Besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis in adults and children. ( 22420526 )
2012
23
Antibiotics versus placebo for acute bacterial conjunctivitis. ( 22972049 )
2012
24
Bacterial conjunctivitis in children: antibacterial treatment options in an era of increasing drug resistance. ( 20724317 )
2011
25
The role of topical moxifloxacin, a new antibacterial in Europe, in the treatment of bacterial conjunctivitis. ( 21604820 )
2011
26
Bacterial conjunctivitis and of antibiotics in Dhulikhel Hospital-Kathmandu University Hospital. ( 22610873 )
2011
27
Efficacy and tolerability of besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study in adults and children. ( 21397770 )
2011
28
Bacterial conjunctivitis in children: a current review of pathogens and treatment. ( 21897142 )
2011
29
Moxifloxacin 0.5% ophthalmic solution: in bacterial conjunctivitis. ( 21175242 )
2011
30
High proportion of nontypeable Streptococcus pneumoniae isolates among sporadic, nonoutbreak cases of bacterial conjunctivitis. ( 21988450 )
2011
31
Microbiological efficacy of a new ophthalmic formulation of moxifloxacin dosed twice-daily for bacterial conjunctivitis. ( 21681652 )
2011
32
Clinical use of gatifloxacin ophthalmic solution for treatment of bacterial conjunctivitis. ( 21573098 )
2011
33
Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: microbiological eradication outcomes. ( 22034555 )
2011
34
Besifloxacin ophthalmic suspension: emerging evidence of its therapeutic value in bacterial conjunctivitis. ( 23861618 )
2011
35
Treatment of bacterial conjunctivitis in children. ( 21323206 )
2011
36
Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile. ( 22034556 )
2011
37
Kinetics of kill of bacterial conjunctivitis isolates with moxifloxacin, a fluoroquinolone, compared with the aminoglycosides tobramycin and gentamicin. ( 20169048 )
2010
38
Peripheral ulcerative keratitis triggered by bacterial conjunctivitis. ( 21141332 )
2010
39
Efficacy and safety of besifloxacin ophthalmic suspension 0.6% in children and adolescents with bacterial conjunctivitis: a post hoc, subgroup analysis of three randomized, double-masked, parallel-group, multicenter clinical trials. ( 20218747 )
2010
40
Effectiveness, tolerability and safety of azithromycin 1% in DuraSite for acute bacterial conjunctivitis. ( 20517467 )
2010
41
Besifloxacin: a topical fluoroquinolone for the treatment of bacterial conjunctivitis. ( 20399984 )
2010
42
Safety and tolerability of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis: data from six clinical and phase I safety studies. ( 20629472 )
2010
43
Efficacy and safety of azithromycin 1.5% eye drops for purulent bacterial conjunctivitis in pediatric patients. ( 19935122 )
2010
44
Identifying children at low risk for bacterial conjunctivitis. ( 20194260 )
2010
45
Bacterial conjunctivitis. ( 21188158 )
2010
46
Bacterial conjunctivitis. ( 21718563 )
2010
47
Limitations of current antibiotics for the treatment of bacterial conjunctivitis. ( 20838353 )
2010
48
Besifloxacin: a novel anti-infective for the treatment of bacterial conjunctivitis. ( 20463787 )
2010
49
Besifloxacin ophthalmic suspension for bacterial conjunctivitis. ( 19927224 )
2009
50
Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis. ( 19323612 )
2009

Variations for Bacterial Conjunctivitis

Expression for Bacterial Conjunctivitis

Search GEO for disease gene expression data for Bacterial Conjunctivitis.

Pathways for Bacterial Conjunctivitis

GO Terms for Bacterial Conjunctivitis

Sources for Bacterial Conjunctivitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....